PT2447254T - Cristais - Google Patents

Cristais

Info

Publication number: PT2447254T
Authority: PT; Portugal
Prior art keywords: crystals
Prior art date: 2009-06-26

Application number

PT107921835T

Other languages

English (en)

Inventor

Itou Hideyuki

Original Assignee

Nippon Shinyaku Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-06-26

Filing date

2010-06-25

Publication date

2018-01-04

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43386634&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT2447254(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2010-06-25 Application filed by Nippon Shinyaku Co Ltd filed Critical Nippon Shinyaku Co Ltd

2018-01-04 Publication of PT2447254T publication Critical patent/PT2447254T/pt

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/20—Nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/20—Nitrogen atoms
- C07D241/22—Benzenesulfonamido pyrazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Diabetes (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Hematology (AREA)
Pulmonology (AREA)
Immunology (AREA)
Urology & Nephrology (AREA)
Physical Education & Sports Medicine (AREA)
Biomedical Technology (AREA)
Endocrinology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Obesity (AREA)
Rheumatology (AREA)
Epidemiology (AREA)
Dermatology (AREA)
Reproductive Health (AREA)
Orthopedic Medicine & Surgery (AREA)
Vascular Medicine (AREA)
Pain & Pain Management (AREA)
Gastroenterology & Hepatology (AREA)
Psychiatry (AREA)
Hospice & Palliative Care (AREA)
Gynecology & Obstetrics (AREA)
Emergency Medicine (AREA)

PT107921835T 2009-06-26 2010-06-25 Cristais PT2447254T (pt)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
JP2009151727		2009-06-26
JP2009151729		2009-06-26
JP2009151728		2009-06-26

Publications (1)

Publication Number	Publication Date
PT2447254T true PT2447254T (pt)	2018-01-04

Family

ID=43386634

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
PT107921835T PT2447254T (pt)	2009-06-26	2010-06-25	Cristais
PT171864150T PT3275871T (pt)	2009-06-26	2010-06-25	Cristais

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
PT171864150T PT3275871T (pt)	2009-06-26	2010-06-25	Cristais

Country Status (33)

Country	Link
US (4)	US8791122B2 (pt)
EP (3)	EP3275871B1 (pt)
JP (1)	JPWO2010150865A1 (pt)
KR (5)	KR102669213B1 (pt)
CN (2)	CN102459198B (pt)
AR (1)	AR077242A1 (pt)
AU (1)	AU2010263569B2 (pt)
BR (2)	BR122021005510B1 (pt)
CA (1)	CA2764475C (pt)
CL (1)	CL2011003264A1 (pt)
CO (1)	CO6430432A2 (pt)
CY (3)	CY1119788T1 (pt)
DK (2)	DK3275871T3 (pt)
ES (2)	ES2797124T3 (pt)
HR (2)	HRP20180171T1 (pt)
HU (3)	HUE048467T2 (pt)
IL (3)	IL216928A (pt)
LT (3)	LT2447254T (pt)
MA (1)	MA33637B1 (pt)
MX (2)	MX346318B (pt)
MY (1)	MY186531A (pt)
NO (2)	NO2447254T3 (pt)
NZ (1)	NZ597352A (pt)
PH (2)	PH12015502824A1 (pt)
PL (2)	PL2447254T3 (pt)
PT (2)	PT2447254T (pt)
RU (1)	RU2556206C3 (pt)
SG (2)	SG10201403313WA (pt)
SI (2)	SI3275871T1 (pt)
SM (2)	SMT201800077T1 (pt)
TW (1)	TWI531565B (pt)
WO (1)	WO2010150865A1 (pt)
ZA (1)	ZA201109099B (pt)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN104761509A (zh) *	2008-02-28	2015-07-08	日本新药株式会社	纤维化抑制剂
US8575175B2 (en)	2008-07-23	2013-11-05	Toray Industries, Inc.	Therapeutic agent for chronic renal failure
CN106279047B (zh) *	2015-05-13	2019-05-03	普济生物科技（台州）有限公司	一种前列环素受体激动剂的制备方法
WO2016193994A1 (en)	2015-05-29	2016-12-08	Megafine Pharma (P) Ltd.	Amorphous selexipag and process for preparation thereof
WO2017029594A1 (en) *	2015-08-17	2017-02-23	Dr. Reddy's Laboratories Limited	Processes for preparation of selexipag and its amorphous form
ES2762943T3 (es)	2015-09-03	2020-05-26	Teva Pharmaceuticals Int Gmbh	Formas de Selexipag en estado sólido
WO2017042828A2 (en) *	2015-09-10	2017-03-16	Megafine Pharma (P) Ltd.	Process for the preparation of selexipag and intermediates thereof
WO2017042731A1 (en)	2015-09-10	2017-03-16	Lupin Limited	Amorphous form of selexipag and solid dispersion thereof
PT4331607T (pt) *	2015-12-02	2025-05-22	Nippon Shinyaku Co Ltd	Composição farmacêutica sólida que contém 2-{4-[n-(5,6-difenilpirazin-2-il)-n-isopropilamino]butiloxi}-n-(metil-sulfonil)acetamida
WO2017109772A1 (en) *	2015-12-20	2017-06-29	Mapi Pharma Ltd.	Amorphous form of selexipag
EP3192502A1 (en)	2016-01-15	2017-07-19	Sandoz Ag	Pharmaceutical composition of selexipag
EP3436439B1 (en) *	2016-04-01	2022-02-16	Honour (R&D)	Process for the preparation of diphenylpyrazine derivatives
CN105949135A (zh) *	2016-05-10	2016-09-21	湖南欧亚生物有限公司	一种赛乐西帕的合成方法
WO2018008042A1 (en) *	2016-07-05	2018-01-11	Maithri Drugs Private Limited	Novel process for the preparation of 2-{4-[(5,6-diphenyl pyrazin-2-yl)(isopropyl)amino]butoxy}-n-(methylsulfonyl)acetamide and novel polymorphs thereof
WO2018015974A1 (en)	2016-07-20	2018-01-25	Mylan Laboratories Limited	Polymorphic forms and amorphous solid dispersion of selexipag
WO2018022704A1 (en) *	2016-07-26	2018-02-01	Teva Pharmaceuticals International Gmbh	Crystalline form vi of selexipag
WO2018078383A1 (en)	2016-10-27	2018-05-03	Cipla Limited	Pharmaceutical composition comprising amorphous selexipag
CN108069914A (zh) *	2016-11-17	2018-05-25	江苏艾立康药业股份有限公司	一种西里帕格晶型的制备方法
MX2019006938A (es)	2016-12-14	2019-09-06	Respira Therapeutics Inc	Metodos y composiciones para trataminto de hipertension pulmonar y otros trastornos del pulmon.
EP3335699A1 (en)	2016-12-15	2018-06-20	H e x a l Aktiengesellschaft	Selexipag formulation in liquisolid system
JOP20190204A1 (ar)	2017-03-08	2019-09-05	Actelion Pharmaceuticals Ltd	تركيبة صيدلانية تشتمل على سيليكسيباغ
BR112020001748A2 (pt)	2017-07-27	2020-07-21	Allergan, Inc.	agonistas de receptor de prostaciclina para redução de gordura corporal
MY202100A (en) *	2017-09-28	2024-04-03	Nippon Shinyaku Co Ltd	Crystal
CN111565720A (zh) *	2017-11-16	2020-08-21	日本新药株式会社	控释制剂
US10407396B2 (en)	2017-11-16	2019-09-10	Apotex Inc.	Crystalline form of selexipag
JP2021512902A (ja)	2018-02-07	2021-05-20	メッドシャインディスカバリーインコーポレイテッド	プロスタサイクリン受容体アゴニスト
TW201936175A (zh) *	2018-02-21	2019-09-16	日商日本新藥股份有限公司	粒狀組合物、粒狀組合物之製造方法、及粒狀組合物之溶出性改善方法
CN109125325B (zh) *	2018-09-25	2021-05-25	中国人民解放军总医院	前列环素受体激动剂的医药用途
WO2020157730A1 (en)	2019-02-03	2020-08-06	Patel Jayendrakumar Dasharathlal	A controlled release pharmaceutical composition of selexipag or it's active metabolite
EP3705115B1 (en)	2019-03-07	2021-06-30	Alfred E. Tiefenbacher (GmbH & Co. KG)	Composition containing selexipag
JP2022532076A (ja)	2019-05-06	2022-07-13	アクテリオンファーマシューティカルズリミテッド	サルコイドーシス関連肺高血圧症の治療方法
JP2022533394A (ja)	2019-05-21	2022-07-22	アクテリオンファーマシューティカルズリミテッド	肺動脈性肺高血圧症の治療を受けている患者のセレキシパグへの移行方法
EP3982967A1 (en)	2019-06-11	2022-04-20	Actelion Pharmaceuticals Ltd.	Methods for treating pulmonary arterial hypertension
WO2021023271A1 (zh) *	2019-08-06	2021-02-11	南京明德新药研发有限公司	作为前列环素受体激动剂的化合物的晶型及其制备方法
CN114555088A (zh)	2019-10-23	2022-05-27	埃科特莱茵药品有限公司	包含赛乐西帕的药物组合物
CA3158292A1 (en)	2019-11-29	2021-06-03	Alessandro MARESTA	Methods of treating pulmonary arterial hypertension
US11969424B2 (en)	2019-12-16	2024-04-30	Tenax Therapeutics, Inc.	Levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction (PH-HFpEF)
WO2021152060A1 (en)	2020-01-31	2021-08-05	Actelion Pharmaceuticals Ltd	Controlled release selexipag composition
WO2021156227A1 (en)	2020-02-03	2021-08-12	Actelion Pharmaceuticals Ltd	Methods of treating and assessing pulmonary arterial hypertension with selexipag
CN112500358B (zh) *	2020-11-18	2022-03-15	江苏豪森药业集团有限公司	赛乐西帕晶型及其制备方法
WO2022106621A1 (en)	2020-11-20	2022-05-27	Actelion Pharmaceuticals Ltd	Selexipag for use via intracolonic administration
TW202241425A (zh)	2021-01-29	2022-11-01	瑞士商艾克泰聯製藥有限公司	用於製造二苯基吡𠯤衍生物之程序
TW202239408A (zh)	2021-01-29	2022-10-16	瑞士商艾克泰聯製藥有限公司	包含二苯基吡𠯤衍生物的醫藥組成物
WO2022238375A1 (en)	2021-05-11	2022-11-17	Actelion Pharmaceuticals Ltd	Methods of treating pulmonary hypertension
US20250064799A1 (en)	2021-12-31	2025-02-27	Tenax Therapeutics, Inc.	Oral formulations of levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction
WO2023131608A1 (en)	2022-01-04	2023-07-13	Actelion Pharmaceuticals Ltd	Controlled release compositions
WO2023214059A1 (en)	2022-05-06	2023-11-09	Actelion Pharmaceuticals Ltd	Diphenylpyrazine compounds as prodrugs
WO2024017964A1 (en)	2022-07-20	2024-01-25	Actelion Pharmaceuticals Ltd	Injectable pharmaceutical composition comprising a diphenylpyrazine derivative
WO2024133620A1 (en)	2022-12-22	2024-06-27	Actelion Pharmaceuticals Ltd	In vitro dissolution test
WO2024142718A1 (ja) *	2022-12-27	2024-07-04	株式会社トクヤマ	セレキシパグのｉ型結晶の製造方法
EP4393476A1 (en) *	2022-12-28	2024-07-03	Sanovel Ilac Sanayi Ve Ticaret A.S.	A tablet formulation comprising selexipag
EP4616904A3 (en)	2022-12-28	2025-10-29	Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi	A formulation comprising selexipag
EP4393475A1 (en)	2022-12-28	2024-07-03	Sanovel Ilac Sanayi Ve Ticaret A.S.	Formulations comprising selexipag
TW202444370A (zh)	2023-03-23	2024-11-16	瑞士商艾克泰聯製藥有限公司	包含二苯基吡衍生物之醫藥組成物
WO2025196095A1 (en)	2024-03-20	2025-09-25	Actelion Pharmaceuticals Ltd	Injectable pharmaceutical composition for treating pulmonary hypertension

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20030092760A1 (en)	2001-03-12	2003-05-15	Toray Industries, Inc.	Therapeutic agent for renal failure
WO2000067748A1 (fr)	1999-05-10	2000-11-16	Toray Industries, Inc.	Remèdes à l'insuffisance rénale
ES2211738T3 (es)	2000-08-03	2004-07-16	Pfizer Products Inc.	Derivados de diazabiciclooctano y sus usos terapeuticos.
JPWO2002085412A1 (ja) *	2001-04-18	2004-08-05	藤沢薬品工業株式会社	組織線維化抑制剤
TWI316055B (pt)	2001-04-26	2009-10-21	Nippon Shinyaku Co Ltd
CN1787824A (zh)	2003-06-25	2006-06-14	有限会社循环器研究所	性交功能改善用外用制剂
US7112393B2 (en)	2003-07-29	2006-09-26	Canon Kabushiki Kaisha	Non-magnetic toner
CN104761509A (zh)	2008-02-28	2015-07-08	日本新药株式会社	纤维化抑制剂
WO2009154246A1 (ja)	2008-06-19	2009-12-23	日本新薬株式会社	勃起不全治療剤
HRP20151443T1 (hr)	2008-06-23	2016-01-29	Nippon Shinyaku Co., Ltd.	Terapijsko sredstvo protiv stenoze kralježniäśnog kanala
CN102065864B (zh)	2008-06-23	2012-11-21	日本新药株式会社	炎性肠病治疗剂
WO2009157397A1 (ja)	2008-06-23	2009-12-30	日本新薬株式会社	非ステロイド性抗炎症剤投与に伴う腸管傷害治療剤
US8575175B2 (en)	2008-07-23	2013-11-05	Toray Industries, Inc.	Therapeutic agent for chronic renal failure
DK2343292T3 (da)	2008-09-10	2014-11-03	Asahi Glass Co Ltd	Nyt prostaglandin 12-derivat

2010
- 2010-06-25 LT LTEP10792183.5T patent/LT2447254T/lt unknown
- 2010-06-25 SG SG10201403313WA patent/SG10201403313WA/en unknown
- 2010-06-25 HU HUE17186415A patent/HUE048467T2/hu unknown
- 2010-06-25 TW TW099120927A patent/TWI531565B/zh not_active IP Right Cessation
- 2010-06-25 AR ARP100102270A patent/AR077242A1/es not_active Application Discontinuation
- 2010-06-25 BR BR122021005510-6A patent/BR122021005510B1/pt not_active IP Right Cessation
- 2010-06-25 PT PT107921835T patent/PT2447254T/pt unknown
- 2010-06-25 PL PL10792183T patent/PL2447254T3/pl unknown
- 2010-06-25 EP EP17186415.0A patent/EP3275871B1/en not_active Revoked
- 2010-06-25 KR KR1020127000526A patent/KR102669213B1/ko active Active
- 2010-06-25 JP JP2011519943A patent/JPWO2010150865A1/ja active Pending
- 2010-06-25 PL PL17186415T patent/PL3275871T3/pl unknown
- 2010-06-25 PT PT171864150T patent/PT3275871T/pt unknown
- 2010-06-25 KR KR1020247016901A patent/KR102705198B1/ko active Active
- 2010-06-25 NO NO10792183A patent/NO2447254T3/no unknown
- 2010-06-25 MX MX2015003876A patent/MX346318B/es unknown
- 2010-06-25 EP EP19219098.1A patent/EP3689855A1/en active Pending
- 2010-06-25 CN CN201080028176.8A patent/CN102459198B/zh active Active
- 2010-06-25 DK DK17186415.0T patent/DK3275871T3/da active
- 2010-06-25 SM SM20180077T patent/SMT201800077T1/it unknown
- 2010-06-25 EP EP10792183.5A patent/EP2447254B1/en active Active
- 2010-06-25 CN CN201410524475.0A patent/CN104326991A/zh active Pending
- 2010-06-25 KR KR1020247016902A patent/KR102829415B1/ko active Active
- 2010-06-25 SI SI201031997T patent/SI3275871T1/sl unknown
- 2010-06-25 BR BRPI1015936-3A patent/BRPI1015936B1/pt active IP Right Grant
- 2010-06-25 MY MYPI2011006259A patent/MY186531A/en unknown
- 2010-06-25 ES ES17186415T patent/ES2797124T3/es active Active
- 2010-06-25 LT LTEP17186415.0T patent/LT3275871T/lt unknown
- 2010-06-25 AU AU2010263569A patent/AU2010263569B2/en active Active
- 2010-06-25 NZ NZ597352A patent/NZ597352A/xx unknown
- 2010-06-25 SG SG2011094083A patent/SG176915A1/en unknown
- 2010-06-25 HU HUE10792183A patent/HUE036721T2/hu unknown
- 2010-06-25 SI SI201031634T patent/SI2447254T1/en unknown
- 2010-06-25 HR HRP20180171TT patent/HRP20180171T1/hr unknown
- 2010-06-25 US US13/379,531 patent/US8791122B2/en active Active
- 2010-06-25 CA CA2764475A patent/CA2764475C/en active Active
- 2010-06-25 SM SM20200177T patent/SMT202000177T1/it unknown
- 2010-06-25 KR KR1020257021877A patent/KR20250107951A/ko active Pending
- 2010-06-25 KR KR1020177005424A patent/KR20170024165A/ko not_active Ceased
- 2010-06-25 RU RU2012102678A patent/RU2556206C3/ru active Protection Beyond IP Right Term
- 2010-06-25 MX MX2011013471A patent/MX2011013471A/es active IP Right Grant
- 2010-06-25 WO PCT/JP2010/060798 patent/WO2010150865A1/ja not_active Ceased
- 2010-06-25 ES ES10792183.5T patent/ES2660007T3/es active Active
- 2010-06-25 DK DK10792183.5T patent/DK2447254T3/en active
2011
- 2011-12-09 ZA ZA2011/09099A patent/ZA201109099B/en unknown
- 2011-12-13 IL IL216928A patent/IL216928A/en active IP Right Grant
- 2011-12-22 CL CL2011003264A patent/CL2011003264A1/es unknown
- 2011-12-26 CO CO11178426A patent/CO6430432A2/es not_active Application Discontinuation
2012
- 2012-01-20 MA MA34554A patent/MA33637B1/fr unknown
2014
- 2014-01-22 US US14/160,699 patent/US9340516B2/en active Active
- 2014-01-22 US US14/160,641 patent/US9284280B2/en active Active
2015
- 2015-06-09 US US14/734,012 patent/US9440931B2/en active Active
- 2015-12-18 PH PH12015502824A patent/PH12015502824A1/en unknown
- 2015-12-18 PH PH12015502825A patent/PH12015502825B1/en unknown
- 2015-12-27 IL IL243287A patent/IL243287B/en active IP Right Grant
- 2015-12-27 IL IL243293A patent/IL243293A0/en unknown
2018
- 2018-01-18 CY CY20181100063T patent/CY1119788T1/el unknown
- 2018-04-11 HU HUS1800015C patent/HUS1800015I1/hu unknown
- 2018-04-11 CY CY2018011C patent/CY2018011I2/el unknown
- 2018-04-18 LT LTPA2018008C patent/LTC2447254I2/lt unknown
- 2018-04-23 NO NO2018015C patent/NO2018015I1/no unknown
2020
- 2020-04-02 HR HRP20200539TT patent/HRP20200539T1/hr unknown
- 2020-04-03 CY CY20201100317T patent/CY1122893T1/el unknown

Also Published As

Publication number	Publication date
HRP20200539T1 (hr)	2020-07-10
PH12015502825A1 (en)	2017-12-11
PT3275871T (pt)	2020-04-21
HUE048467T2 (hu)	2020-07-28
RU2556206C2 (ru)	2015-07-10
RU2012102678A (ru)	2013-08-10
US20140148469A1 (en)	2014-05-29
LT3275871T (lt)	2020-05-11
CL2011003264A1 (es)	2012-07-06
PL2447254T3 (pl)	2018-05-30
JPWO2010150865A1 (ja)	2012-12-10
MY186531A (en)	2021-07-25
US8791122B2 (en)	2014-07-29
LT2447254T (lt)	2018-01-10
US8791122C1 (pt)	2014-07-29
US9284280B2 (en)	2016-03-15
KR20120109457A (ko)	2012-10-08
BR122021005510B1 (pt)	2022-01-11
KR20250107951A (ko)	2025-07-14
IL243293A0 (en)	2016-02-29
KR102829415B1 (ko)	2025-07-03
CY2018011I1 (el)	2018-09-05
US20150266830A1 (en)	2015-09-24
CA2764475C (en)	2017-04-25
PL3275871T3 (pl)	2020-07-27
KR102669213B1 (ko)	2024-05-28
US20120101276A1 (en)	2012-04-26
IL216928A0 (en)	2012-02-29
ZA201109099B (en)	2012-08-29
MX2011013471A (es)	2012-01-30
AU2010263569B2 (en)	2016-08-18
IL243287A0 (en)	2016-02-29
LTC2447254I2 (lt)	2022-04-25
CN104326991A (zh)	2015-02-04
NZ597352A (en)	2013-01-25
US9340516B2 (en)	2016-05-17
CY2018011I2 (el)	2018-09-05
PH12015502825B1 (en)	2017-12-11
HK1244788A1 (en)	2018-08-17
CN102459198A (zh)	2012-05-16
CA2764475A1 (en)	2010-12-29
HUE036721T2 (hu)	2018-07-30
CY1119788T1 (el)	2018-06-27
KR20240090716A (ko)	2024-06-21
US9440931B2 (en)	2016-09-13
WO2010150865A1 (ja)	2010-12-29
SG10201403313WA (en)	2014-10-30
SMT202000177T1 (it)	2020-05-08
EP2447254A4 (en)	2012-12-19
SG176915A1 (en)	2012-01-30
LTPA2018008I1 (lt)	2018-05-10
CN102459198B (zh)	2014-09-24
TWI531565B (zh)	2016-05-01
EP3275871A1 (en)	2018-01-31
ES2797124T3 (es)	2020-12-01
TW201111352A (en)	2011-04-01
KR20240090717A (ko)	2024-06-21
ES2660007T3 (es)	2018-03-20
HRP20180171T1 (hr)	2018-03-09
HUS1800015I1 (hu)	2018-05-28
KR102705198B1 (ko)	2024-09-11
NO2447254T3 (pt)	2018-05-05
IL243287B (en)	2021-04-29
SI3275871T1 (sl)	2020-06-30
AR077242A1 (es)	2011-08-10
SMT201800077T1 (it)	2018-03-08
IL216928A (en)	2016-10-31
CO6430432A2 (es)	2012-04-30
MA33637B1 (fr)	2012-10-01
SI2447254T1 (en)	2018-03-30
PH12015502824A1 (en)	2017-05-29
CY1122893T1 (el)	2021-05-05
KR20170024165A (ko)	2017-03-06
EP3689855A1 (en)	2020-08-05
DK2447254T3 (en)	2018-01-15
EP2447254A1 (en)	2012-05-02
US20140155414A1 (en)	2014-06-05
AU2010263569A1 (en)	2012-02-02
EP3275871B1 (en)	2020-01-15
BRPI1015936B1 (pt)	2021-07-13
EP2447254B1 (en)	2017-12-06
NO2018015I1 (no)	2018-04-23
BRPI1015936A2 (pt)	2016-08-16
RU2556206C3 (ru)	2021-06-15
MX346318B (es)	2017-03-15
DK3275871T3 (da)	2020-04-06

Publication	Publication Date	Title
LTPA2018008I1 (lt)	2018-05-10	Kristalai
BRPI1008774A2 (pt)	2016-03-08	espiroamida substituída
DK2411442T4 (da)	2021-12-06	Umættet polyesterresin
DE112010004215A5 (de)	2012-08-23	Hydrostataktor
EP2469625A4 (en)	2015-11-04	OMNIBUS BAR
EP2445547A4 (en)	2012-12-12	CATHETERISM SYSTEM
DK2430035T3 (da)	2013-05-27	Uracylspipooxetannukleosider
BRPI1008827A2 (pt)	2016-02-23	deisobutenizador
BRPI1014968A2 (pt)	2016-12-13	subalargador
DE112010002728A5 (de)	2012-06-21	Turboinhalator
DE112010004249A5 (de)	2012-11-29	Spindelaktor
DE112009005323A5 (de)	2012-07-26	Hebelarmprüfmaschine
BRPI1008070A2 (pt)	2016-03-15	tricianoboratos
BR112012004964A2 (pt)	2016-04-05	girocóptero
EP2409976A4 (en)	2012-09-19	GLYCINE TRANSPORTER INHIBITOR
DK2483126T3 (da)	2015-06-22	Skinnekøretøj
DE112010004865T8 (de)	2013-01-24	Lamellennassreibkupplung
DK2506968T3 (da)	2020-11-23	Faujasit-zeolit
DE112010003255A5 (de)	2013-05-02	Fördergutverteiler
EP2454221A4 (en)	2012-05-23	cineole
BRPI1010159A2 (pt)	2016-03-29	bistuti
EP2398476A4 (en)	2013-09-11	Policosanol nanoparticles
EP2518828A4 (en)	2015-04-01	Rfid tag
EP2448583A4 (en)	2012-12-05	Substituted 4-hydroxypyrimidine-5-carboxamides
BR112012003616A2 (pt)	2016-02-23	metilpirroloprimidinacarboxamidas